Spyre Therapeutics, Inc. — Director's Dealing 2016

Apr 12, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2016-04-12

Reporting Person: TYLER JOSEPH E (VP, Manufacturing)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-04-12	Common Stock	C	31260	—	Acquired	42428	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-04-12	Series A Preferred Stock	$0	C	22857	Disposed		Common Stock (22857)	Direct
2016-04-12	Series B Preferred Stock	$0	C	8403	Disposed		Common Stock (8403)	Direct

Footnotes

F1: In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.